World Heart Federation. What is cardiovascular disease? https://world-heart-federation.org/what-is-cvd/. Accessed Oct 15, 2023.

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.

Article  PubMed  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143.

PubMed  Google Scholar 

Bruckert E, Catapano AL, Farnier M, et al. The clinician’s handbook: dyslipidaemia and atherosclerosis prevention, diagnosis and treatment 2019 - update 2023. https://eas-society.org/publications/clinicians-handbook/. Accessed Apr 1, 2024.

Chan RH, Chan PH, Chan KK, et al. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre. Hong Kong Med J. 2012;18:395–406.

PubMed  Google Scholar 

Park JE, Chiang C-E, Munawar M, et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol. 2012;19:781–94.

Article  PubMed  Google Scholar 

Koh N, Ference BA, Nicholls SJ, et al. Asian Pacific Society of Cardiology consensus recommendations on dyslipidaemia. Eur Cardiol. 2021;16:e54.

Article  PubMed  PubMed Central  Google Scholar 

Chee YJ, Chan HH, Tan NC. Understanding patients’ perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review. Singapore Med J. 2014;55:416–21.

Article  PubMed  PubMed Central  Google Scholar 

Amgen Inc. Repatha prescribing information (United States). https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Repatha/repatha_pi_hcp_english.pdf. Accessed Oct 15, 2023.

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.

Article  CAS  PubMed  Google Scholar 

Joint Committee for Guideline Revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15:1–29.

PubMed Central  Google Scholar 

Colletti A, Derosa G, Cicero AF. Retargeting the management of hypercholesterolemia - focus on evolocumab. Ther Clin Risk Manag. 2016;12:1365–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray KK, Dhalwani N, Sibartie M, et al. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. Eur Heart J Qual Care Clin Outcomes. 2022;8:447–60.

Article  PubMed  PubMed Central  Google Scholar 

Gupta M, Mancini GBJ, Wani RJ, et al. Real-world insights into evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study. CJC Open. 2022;4:558–67.

Article  PubMed  PubMed Central  Google Scholar 

Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardio. 2021;6:1060–8.

Article  Google Scholar 

Amgen Inc. Press release. Amgen receives NMPA approval for Repatha (evolocumab) in China to reduce the risk of cardiovascular events. https://www.amgen.com/newsroom/press-releases/2019/01/amgen-receives-nmpa-approval-for-repatha-evolocumab-in-china-to-reduce-the-risk-of-cardiovascular-events. Accessed Oct 20, 2023.

Amgen Inc. Press release. Amgen’s Repatha (evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol. https://www.amgen.com/newsroom/press-releases/2016/01/amgens-repatha-evolocumab-approved-as-first-pcsk9-inhibitor-in-japan-for-the-treatment-of-high-cholesterol. Accessed Oct 20, 2023.

Lin JL, Chen PS, Lin HW, Tsai LM, Lin SH, Li YH. Real-world analyses of the safety outcome among a general population treated with statins: an Asian population-based study. J Atheroscler Thromb. 2022;29:1213–25.

Article  CAS  PubMed  Google Scholar 

Yan BP, Chan CK, Wong MC, To OT, Lee VW. Long-term efficacy of lower intensity statin therapy in Chinese acute coronary syndrome patients. Value Health. 2018;21(Suppl 2):S26.

Google Scholar 

Chien SC, Chen PS, Huang YH, Tang SC, Li YH, Yeh HI. 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance. J Formos Med Assoc. 2019;118:1385–92.

Article  PubMed  Google Scholar 

Arnold SV, Cannon CP, de Lemos JA, et al. What do US physicians and patients think about lipid-lowering therapy and goals of treatment? Results from the GOULD registry. J Am Heart Assoc. 2021;10: e020893.

Article  PubMed  PubMed Central  Google Scholar 

Tai MH, Shepherd J, Bailey H, et al. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom. Curr Med Res Opin. 2019;35:829–35.

Article  CAS  PubMed  Google Scholar 

Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2020;28:1279–89.

Article  Google Scholar 

Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624.

Article  PubMed  PubMed Central  Google Scholar 

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imag. 2022;15:1308–21.

Article  Google Scholar 

Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327:1771–81.

Article  PubMed  PubMed Central  Google Scholar 

Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. Am J Cardiol. 2016;117:40–7.

Article  CAS  PubMed  Google Scholar 

Koba S, Inoue I, Cyrille M, et al. Evolocumab vs ezetimibe in statin-intolerant hyperlipidemic Japanese patients: phase 3 GAUSS-4 trial. J Atheroscler Thromb. 2020;27:471–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirayama A, Yamashita S, Ruzza A, et al. Long-term treatment with evolocumab among Japanese patients - final report of the OSLER open-label extension studies. Circ J. 2019;83:971–7.

Article  CAS  PubMed  Google Scholar 

Bansal S, Ruzza A, Sawhney J, et al. Evolocumab in patients with homozygous familial hypercholesterolemia in India. J Clin Lipidol. 2021;15:814–21.

Article  PubMed  Google Scholar 

Tan H, Li W, Huang Z, et al. Efficacy and safety of evolocumab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia: 12-week primary results of the HUA TUO randomized clinical trial. Cardiol Ther. 2023;12:341–59.

Article  PubMed  PubMed Central  Google Scholar 

Blom DJ, Chen J, Yuan Z, et al. Effects of evolocumab therapy and low LDL-C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes. Endocrinol Diabetes Metab. 2020;3:e00123.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Yuan Z, Lu J, et al. Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: pre-specified analysis of the Chinese population from the BERSON clinical trial. Diabetes Obes Metab. 2019;21:1464–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin DY, Tsai CL, Chang YH, et al. Real-world data on comparison of lipid-lowering effects between alirocumab and evolocumab in patients with hypercholesterolemia. Acta Cardiol Sin. 2022;38:778–83.

PubMed  PubMed Central  Google Scholar 

Lin PL, Wu YW, Lin CF, et al. Real-world analyses of the treatment conditions in patients initiating proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Taiwan. J Atheroscler Thromb. 2023;30:1123–31.

Article  CAS  PubMed